People Background Check
Find People:

Chao GuoOakland, CA

Get Report

Chao Guo Phones & Addresses

Emeryville, CA

Mentions for Chao Guo

Career records & work history

Lawyers & Attorneys

Chao Guo Photo 1

Chao Guo - Lawyer

ISLN:
923641398
Admitted:
2013

Chao Guo resumes & CV records

Resumes

Chao Guo Photo 35

Legal Intern At Federal Communications Commission

Position:
Legal Intern at Federal Communications Commission
Location:
Washington, District Of Columbia
Industry:
Law Practice
Work:
Federal Communications Commission - Washington, DC since May 2012
Legal Intern Alliance of Artists and Recording Companies - Alexandria, Virginia Jul 2011 - Dec 2011
Law Clerk Walt Disney World May 2008 - Jun 2010
Attractions Host Exploris 2003 - 2004
Intern
Education:
American University, Washington College of Law 2010 - 2013
JD University of Virginia 2004 - 2007
BA, English, International Relations High School
Skills:
Legal Research

Publications & IP owners

Us Patents

Bcma-Directed Cellular Immunotherapy Compositions And Methods

US Patent:
2023002, Jan 26, 2023
Filed:
Jan 11, 2021
Appl. No.:
17/758116
Inventors:
- South San Francisco CA, US
James Barnaby Trager - Albany CA, US
Luxuan Guo Buren - San Francisco CA, US
Chao Guo - San Francisco CA, US
Alexandra Leida Liana Lazetic - San Jose CA, US
International Classification:
A61K 35/17
C07K 16/28
C07K 14/705
C07K 14/725
C07K 14/715
A61P 35/00
Abstract:
Provided for herein in several embodiments are immune cell-based compositions comprising BCMA-directed chimeric antigen receptors (CAR). In several embodiments, the immune-cell based compositions also target an additional tumor marker and/or an additional epitope of BCMA. In several embodiments, the BCMA-directed CAR is expressed in a Natural Killer cell. In several embodiments, combinations of BCMA-CAR-expressing NK cells are administered in conjunction with, for example CAR-expressing NK cells and/or CAR-expressing T cells that are directed to an additional cancer marker and/or an additional epitope of BCMA. Also provided for herein are methods and uses of the chimeric antigen receptors in immunotherapy.

Truncated Nkg2D Chimeric Receptors And Uses Thereof In Natural Killer Cell Immunotherapy

US Patent:
2023000, Jan 5, 2023
Filed:
May 10, 2022
Appl. No.:
17/740899
Inventors:
- Singapore, SG
- South San Francisco CA, US
See Voon Seow - Singapore, SG
Dario Campana - Singapore, SG
James Barnaby Trager - Albany CA, US
Alexandra Leida Liana Lazetic - San Jose CA, US
Chao Guo - San Francisco CA, US
Luxuan Guo Buren - San Francisco CA, US
Shyam Sashikant Masrani - London, GB
International Classification:
C07K 14/705
C07K 14/54
C07K 14/725
C12N 15/62
Abstract:
Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.

Cd19-Directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy

US Patent:
2021007, Mar 11, 2021
Filed:
Nov 4, 2020
Appl. No.:
17/089449
Inventors:
- South San Francisco CA, US
Luxuan Guo Buren - San Francisco CA, US
Chao Guo - San Francisco CA, US
Mira Tohmé - San Francisco CA, US
Ivan Chan - Millbrae CA, US
Alexandra Leida Liana Lazetic - San Jose CA, US
International Classification:
C07K 16/28
C07K 14/705
C07K 14/725
C07K 14/54
Abstract:
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

Immune Cells Engineered To Express Cd19-Directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy

US Patent:
2021007, Mar 11, 2021
Filed:
Nov 4, 2020
Appl. No.:
17/089578
Inventors:
- South San Francisco CA, US
Luxuan Guo Buren - San Francisco CA, US
Chao Guo - San Francisco CA, US
Mira Tohmé - San Francisco CA, US
Ivan Chan - Millbrae CA, US
Alexandra Leida Liana Lazetic - San Jose CA, US
International Classification:
C07K 16/28
C12N 5/0783
C07K 14/705
C07K 14/725
Abstract:
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

Cancer Immunotherapy Using Cd19-Directed Chimeric Antigen Receptors

US Patent:
2021006, Mar 4, 2021
Filed:
Nov 4, 2020
Appl. No.:
17/089474
Inventors:
- South San Francisco CA, US
Luxuan Guo Buren - San Francisco CA, US
Chao Guo - San Francisco CA, US
Mira Tohmé - San Francisco CA, US
Ivan Chan - Millbrae CA, US
Alexandra Leida Liana Lazetic - San Jose CA, US
International Classification:
A61K 35/17
C07K 16/28
A61P 35/00
C07K 14/705
C07K 14/725
C07K 14/54
C07K 14/55
Abstract:
Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.

Resource-Aware Large-Scale Cooperative 3D Mapping Using Multiple Mobile Devices

US Patent:
2017034, Nov 30, 2017
Filed:
May 25, 2017
Appl. No.:
15/605448
Inventors:
- Minneapolis MN, US
- Mountain View CA, US
Joel Hesch - Mountain View CA, US
Chao Guo - Minneapolis MN, US
Ryan C. DuToit - San Jose CA, US
Kourosh Sartipi - Santa Clara CA, US
Georgios Georgiou - San Francisco CA, US
International Classification:
G01C 21/16
G06T 17/00
G06T 17/05
G06T 19/00
Abstract:
A method includes: receiving, with a computing platform, respective trajectory data and map data independently generated by each of a plurality of vision-aided inertial navigation devices (VINS devices) traversing an environment, wherein the trajectory data specifies poses along a path through the environment for the respective VINS device and the map data specifies positions of observed features within the environment as determined by an estimator executed by the respective VINS device; determining, with the computing platform and based on the respective trajectory data and map data from each of the VINS devices, estimates for relative poses within the environment by determining transformations that geometrically relate the trajectory data and the map data between one or more pairs of the VINS devices; and generating, with the computing platform and based on the transformations, a composite map specifying positions within the environment for the features observed by the VINS devices.

Possible Relatives

David Y Guo  Dennis Guo  Elvis L Guo  Fan Guo  Feng Guo  Gang Guo  Hou Z Guo  Chao X Thao  Chao J Wei  Chao K Peng 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.